



Integra LifeSciences Highlights New LED Headlight System at North American Spine Society Annual Meeting

PLAINSBORO, N.J., Nov. 3, 2011 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corp.](#) (Nasdaq:IART) today announced that it is featuring the new Integra™ LED Headlight System at the North American Spine Society (NASS) Annual Meeting in Chicago, Illinois, November 2-5, 2011.

The Integra™ LED Headlight System is the latest addition to Integra's surgical lighting product portfolio, and offers a 25,000+ hour lamp, providing cool brightness and the vibrant color rendition that maximizes visualization of critical anatomy across a broad range of surgical procedures. The LED Headlight System also provides greater mobility with either a lightweight 20-foot power cord that eliminates the clutter of floor stands and fiber optic cables, or a light weight battery option that allows surgeons untethered mobility within the operating room.

"We're very pleased to offer surgeons a low cost, self-contained surgical headlight that doesn't require fiber optic cords, and provide them with a new level of independence by allowing them to move more freely about the operating room," said Dan Reuvers, President, Instruments.

Integra currently offers an extensive range of surgical illumination products and accessories, including the Integra™ Luxtec® MLX 300W Xenon system, Integra™ Luxtec® 9300 XSP 300W Xenon system, Integra™ ProXenon® 300W Xenon system, as well as Integra™ UltraLite® Pro and CoolVent™ headlight systems.

[Integra LifeSciences](#), a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use the products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Gianna Sabella

Director, Corporate Communications

(609) 936-2389

gianna.sabella@integralife.com